标题
Identification of benzothiazoles as novel PCSK9 inhibitors
作者
关键词
-
出版物
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume -, Issue -, Pages 129542
出版商
Elsevier BV
发表日期
2023-11-07
DOI
10.1016/j.bmcl.2023.129542
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia ― A Post-Marketing Survey (J-POSSIBLE) ―
- (2023) Arihiro Kiyosue et al. CIRCULATION JOURNAL
- Global cardiovascular diseases death rate prediction
- (2023) Oleg Gaidai et al. CURRENT PROBLEMS IN CARDIOLOGY
- Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
- (2022) Shakir Ahamad et al. DRUG DISCOVERY TODAY
- PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin‐treated patients with very high apolipoprotein(a) concentration
- (2022) Qidi Ying et al. JOURNAL OF INTERNAL MEDICINE
- Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system
- (2022) Chunmei Ji et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis
- (2022) Meng-Qian Qiao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The changing landscape of atherosclerosis
- (2021) Peter Libby NATURE
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- (2021) Frank L J Visseren et al. European Journal of Preventive Cardiology
- A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α
- (2020) Xuelei Wang et al. EBioMedicine
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Cholesterol-Lowering Agents
- (2019) Savvas Hadjiphilippou et al. CIRCULATION RESEARCH
- Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease
- (2019) Ralph Kwame Akyea et al. HEART
- Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors
- (2019) Carmen Lammi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
- (2018) Allyn T. Londregan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecule Inhibitors of the PCSK9·LDLR Interaction
- (2018) Jaru Taechalertpaisarn et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
- (2017) Aris Karatasakis et al. Journal of the American Heart Association
- Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic
- (2016) Mattia Stucchi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL
- (2016) Paulina Bartuzi et al. Nature Communications
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
- (2015) Lee Joseph et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells
- (2014) Mi-Hsueh Tai et al. MOLECULAR NUTRITION & FOOD RESEARCH
- Pharmacological strategies for lowering LDL cholesterol: statins and beyond
- (2011) Ariel Brautbar et al. Nature Reviews Cardiology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started